VENTURE CAPITAL FUNDING FOR BIOTECHS INCREASES 39% TO $639 MIL IN 12 MONTHS; ERNST & YOUNG PREDICTS MORE STRATEGIC REFOCUSINGS TO AVOID CASH CRUNCH
Executive Summary
Biotech companies at a variety of developmental stages are raising increasing amounts of cash from venture capital firms, according to figures compiled by Ernst & Young in its Biotech 95 report.